Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 17

Scientific Reports

The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of action of empagliflozin in HFpEF at the molecular level. We retrieved information regarding HFpEF...

  • Really interesting article using in silico and in vivo techniques to try and elucidate SGLT2i mechanism of action in heart failure.